Administration of Nivolumab plus FOLFOX Therapy to a Patient with Gastric Cancer Undergoing Hemodialysis: A Case Report
The optimal dose of chemotherapy for patients undergoing hemodialysis remains unclear. A 65-year-old man with diabetic nephropathy was treated with nivolumab plus modified FOLFOX6 therapy for recurrent gastric cancer with liver metastases. Oxaliplatin was reduced to 65 mg/m<sup>2</sup>, continuous infusion of 5-fluorouracil was initiated at 2,000 mg/m<sup>2</sup>, and bolus administration was discontinued. No nivolumab was administrated. Dose modification and discontinuation were performed depending on the patient's general condition and blood test during the treatment course. He received standard chemotherapy for gastric cancer; however, it was ineffective because of ascites and elevated CA125 levels.
Authors
- Taichi Yoshida (ORCID: https://orcid.org/0000-0002-6912-3223)
- Koji Fukuda (ORCID: https://orcid.org/0000-0002-1271-1796)
- Daiki Taguchi (ORCID: https://orcid.org/0000-0003-3426-8251)
- Tomohiro Matsumoto (ORCID: https://orcid.org/0000-0002-2375-4919)
- Nobuhiro Kodama (ORCID: https://orcid.org/0000-0002-6334-4367)
- Kazuhiro Shimazu
- Hiroyuki Shibata (ORCID: https://orcid.org/0000-0003-3581-3506)
Institutions
- Akita University (JP)
- Akita Red Cross Hospital (JP)
Publication Details
- Journal
- Internal Medicine
- Published
- 2025-01-01
- DOI
- https://doi.org/10.2169/internalmedicine.5874-25
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00